Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Bayer/Onyx Pharma’s Nexavar Among MHLW’s Pre-Golden Week Approval Rush

This article was originally published in PharmAsia News

Executive Summary

Japan's Ministry of Health, Labor and Welfare's drug approval advisory body, the Pharmaceutical Affairs and Food Sanitization Council's second committee on new drugs April 27 recommended Bayer/Onyx Pharmaceuticals' Nexavar (sorafenib) for approval for the additional indication of advanced hepatocellular carcinoma

You may also be interested in...

No Joy In Bayer/Onyx’s Phase III With Nexavar For Melanoma

Second sorafenib failure comes three months after Synta/GlaxoSmithKline’s elesclomol blow-up in the tough-to-crack cancer.

Genzyme Strengthens Oncology And MS Portfolios With Bayer Deal

The complicated deal bolsters Genzyme’s developing oncology franchise and provides a potential MS blockbuster without requiring an up-front payment.

PharmAsia News Business Bulletin

A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts